Effect of mazindol on growth hormone levels in patients with Duchenne muscular dystrophy.
Human growth hormone (HGH) inhibition may be beneficial in Duchenne muscular dystrophy (DMD) and slow down the rate of progression of the disease. The purposes of the present investigation were: 1) to assess, through pharmacological stimuli (L-dopa test), the HGH response in untreated DMD patients, and 2) to evaluate the inhibitory effect of mazindol on HGH levels as a potential treatment for DMD. In 55 DMD patients, HGH levels were measured through the L-dopa test, and 40 received mazindol. After 1 year, there was wide variability in the individual response to mazindol. An apparent diminution in the mean HGH level was observed in the whole group of patients; this was statistically significant after 3 and 6 months but not after 9 and 12 months of treatment. The results suggest that this drug is not effective for arresting growth or inhibiting HGH secretion for a prolonged period of time.
Zatz
M
M
Departamento de Biologia, Universidade de São Paulo, Brazil.
Rapaport
D
D
Vainzof
M
M
Pavanello
R de C
Rde C
Rocha
J M
JM
Betti
R T
RT
Otto
P A
PA
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D007980:Levodopa; D008297:Male; D008454:Mazindol / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D009136:Muscular Dystrophies / Q000097:blood* / Q000188:drug therapy
D007211:Indoles; D007980:Levodopa; D013006:Growth Hormone; D008454:Mazindol